Hamlet BioPharma AB (publ)

NGM:HAMLET B Stock Report

Market Cap: SEK 617.4m

Hamlet BioPharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Martin Erixon

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.3yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure3.8yrs

Recent management updates

Recent updates

Is Hamlet Pharma (NGM:HAMLET B) In A Good Position To Invest In Growth?

Jul 04
Is Hamlet Pharma (NGM:HAMLET B) In A Good Position To Invest In Growth?

Here's Why We're Watching Hamlet Pharma's (NGM:HAMLET B) Cash Burn Situation

Mar 04
Here's Why We're Watching Hamlet Pharma's (NGM:HAMLET B) Cash Burn Situation

We Think Hamlet Pharma (NGM:HAMLET B) Can Afford To Drive Business Growth

Nov 10
We Think Hamlet Pharma (NGM:HAMLET B) Can Afford To Drive Business Growth

We Think Hamlet Pharma (NGM:HAMLET B) Can Easily Afford To Drive Business Growth

Jun 17
We Think Hamlet Pharma (NGM:HAMLET B) Can Easily Afford To Drive Business Growth

Companies Like Hamlet Pharma (NGM:HAMLET B) Are In A Position To Invest In Growth

Oct 12
Companies Like Hamlet Pharma (NGM:HAMLET B) Are In A Position To Invest In Growth

Will Hamlet Pharma (NGM:HAMLET B) Spend Its Cash Wisely?

Mar 17
Will Hamlet Pharma (NGM:HAMLET B) Spend Its Cash Wisely?

CEO

Martin Erixon

1.3yrs

Tenure

Mr. Martin Erixon serves as Chief Executive Officer of Hamlet BioPharma AB (publ) (formerly known as Hamlet Pharma AB (publ)) since October 11, 2023. He was Chief Executive Officer of Hamlet BioPharma AB (...

Board Members

NamePositionTenureCompensationOwnership
Catharina Svanborg
Founder & Chairman of the Boardno datano data20.9%
SEK 129.0m
Elisabeth Parker
Director1.1yrsno datano data
Helena Lomberg
Director7yrsno datano data
Bill Hansson
Director3.8yrsno datano data
Ulla Tragardh
Directorno datano datano data
Magnus Nylén
Directorno datano datano data

3.8yrs

Average Tenure

Experienced Board: HAMLET B's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 06:56
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hamlet BioPharma AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution